Table 2

Ongoing Phase I/II trials of solid tumors at CWRU requiring sequential tumor biopsies for pharmacodynamic end points

TrialTumor typePharmacodynamic end points
Phase I pharmacodynamic trial of SU5416Advanced solid tumorsMicrovessel density, apoptotic rate, and proliferative rate
Phase Ib/II trial of SU5416 and doxorubicin in inflammatory breast cancerInflammatory breast cancerMicrovessel density, apoptotic rate, and proliferative rate
Phase Ib/II trial of SU5416 and paclitaxel in head and neck cancerHead and neck cancerMicrovessel density, apoptotic rate, and proliferative rate
Phase I trial of fenretinide, cisplatin, and paclitaxelAdvanced solid tumorsApoptosis, retinoid receptor function, and TIG3 expression
Phase II trial of O6BG and BCNU in malignant melanomaMalignant melanomaDepletion of alkylguanine DNA alkyltransferase
Phase I trial of CI-1033Colon cancerExpression and activation of the epidermal growth factor receptor, ERK1/ERK2,a and AKT pathways
  • a ERK, extracellular signal-regulated kinase.